Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR S&P Pharmaceuticals ETF (XPH), we found that the implied analyst target price for the ETF based upon its underlying holdings is $51.90 per unit.

10 ETFs With Most Upside To Analyst Targets »

With XPH trading at a recent price near $43.97 per unit, that means that analysts see 18.05% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of XPH's underlying holdings with notable upside to their analyst target prices are Omeros Corp ( OMER), MyoKardia Inc ( MYOK), and Revance Therapeutics Inc ( RVNC). Although OMER has traded at a recent price of $19.32/share, the average analyst target is 47.00% higher at $28.40/share. Similarly, MYOK has 45.86% upside from the recent share price of $37.25 if the average analyst target price of $54.33/share is reached, and analysts on average are expecting RVNC to reach a target price of $45.14/share, which is 32.38% above the recent price of $34.10. Below is a twelve month price history chart comparing the stock performance of OMER, MYOK, and RVNC:

OMER, MYOK, and RVNC Relative Performance Chart

Below is a summary table of the current analyst target prices discussed above:

Name Symbol Recent Price Avg. Analyst 12-Mo. Target % Upside to Target
SPDR S&P Pharmaceuticals ETF XPH $43.97 $51.90 18.05%
Omeros Corp OMER $19.32 $28.40 47.00%
MyoKardia Inc MYOK $37.25 $54.33 45.86%
Revance Therapeutics Inc RVNC $34.10 $45.14 32.38%

Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.

The average analyst target price data upon which this article was based, is courtesy of data provided by Zacks Investment Research via Quandl.com.
Get the latest Zacks research report on OMER — FREE
Get the latest Zacks research report on MYOK — FREE
Get the latest Zacks research report on RVNC — FREE